Palvella Therapeutics (PVLA) EBIAT (2016 - 2024)
Historic EBIAT for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$4.0 million.
- Palvella Therapeutics' EBIAT fell 11021.17% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 19327.48%. This contributed to the annual value of -$17.4 million for FY2024, which is 19327.48% down from last year.
- As of Q4 2024, Palvella Therapeutics' EBIAT stood at -$4.0 million, which was down 11021.17% from -$6.8 million recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' EBIAT registered a high of $38.7 million during Q4 2023, and its lowest value of -$16.5 million during Q3 2021.
- Over the past 5 years, Palvella Therapeutics' median EBIAT value was -$7.4 million (recorded in 2022), while the average stood at -$5.8 million.
- In the last 5 years, Palvella Therapeutics' EBIAT plummeted by 169551.12% in 2020 and then skyrocketed by 57619.69% in 2023.
- Palvella Therapeutics' EBIAT (Quarter) stood at -$14.4 million in 2020, then surged by 33.81% to -$9.5 million in 2021, then grew by 14.76% to -$8.1 million in 2022, then soared by 576.2% to $38.7 million in 2023, then crashed by 110.21% to -$4.0 million in 2024.
- Its last three reported values are -$4.0 million in Q4 2024, -$6.8 million for Q3 2024, and -$4.2 million during Q2 2024.